Association of Overexpression of Hexokinase II with Chemoresistance in Epithelial Ovarian Cancer

Overview

Journal Clin Exp Med

Specialty General Medicine

Date 2013 Aug 17

PMID 23949336

Citations 47

Authors

Dong Hoon Suh

Min A Kim

Haeryoung Kim

Mi-Kyung Kim

Hee Seung Kim

Hyun Hoon Chung

Yong-Beom Kim

Yong Sang Song

Affiliations

Soon will be listed here.

Abstract

This aim of this study was to evaluate the relationship between hexokinase II expression and chemoresistance in epithelial ovarian cancer. One hundred and eleven paraffin-embedded specimens from patients with epithelial ovarian cancer were immunohistochemically stained for hexokinase II. Subsequently, the association between hexokinase II overexpression and clinicopathologic characteristics including chemoresistance was assessed. Survival analyses were also performed for evaluating the prognostic value of hexokinase II overexpression. Tumor recurrence within 6 months after termination of first-line chemotherapy was considered to indicate chemoresistance. Hexokinase II overexpression was associated with chemoresistance (p = 0.029) and was an independent risk factor for chemoresistance [odds ratio (OR) 3.37; 95 % confidence interval (CI) 1.07-10.62; p = 0.038] along with non-optimal debulking surgery (OR 4.93; 95 % CI 1.43-16.98; p = 0.011). Hexokinase II overexpression was significantly associated with decreased progression-free survival (p = 0.002) and showed a similar trend for overall survival (p = 0.101). Cox regression analysis revealed that hexokinase II overexpression was an independent prognostic factor for early recurrence (hazard ratio 2.63; 95 % CI 1.40-4.92; p = 0.002). Our findings suggest that hexokinase II overexpression is associated with short progression-free survival, which could be associated with chemoresistance in epithelial ovarian cancer.

Citing Articles

Competing endogenous RNA networks in ovarian cancer: from bench to bedside.

Derogar R, Nejadi Orang F, Shadbad M EXCLI J. 2025; 24:86-112.

PMID: 39967908 PMC: 11830916. DOI: 10.17179/excli2024-7827.

MicroRNA155 in non-small cell lung cancer: a potential therapeutic target.

Wei X, Xiong X, Chen Z, Chen B, Zhang C, Zhang W Front Oncol. 2025; 15:1517995.

PMID: 39963112 PMC: 11830606. DOI: 10.3389/fonc.2025.1517995.

Proton Sensing GPCR's: The missing link to Warburg's Oncogenic Legacy?.

Cornell J, Rea S, Neitzel L, Williams C, Hong C J Cancer Biol. 2024; 5(2):65-75.

PMID: 39641117 PMC: 11619763. DOI: 10.46439/cancerbiology.5.066.

Hexokinase 2 as an independent risk factor for worse patient survival in esophageal adenocarcinoma and as a potential therapeutic target protein: A retrospective, single‑center cohort study.

Lyu S, Simon A, Jung J, Fretter C, Schroder W, Bruns C Oncol Lett. 2024; 28(4):495.

PMID: 39211305 PMC: 11358717. DOI: 10.3892/ol.2024.14628.

Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer.

Kim M, Glassman D, Handley K, Lankenau Ahumada A, Jennings N, Bayraktar E Cancer Med. 2024; 13(15):e70031.

PMID: 39114948 PMC: 11306972. DOI: 10.1002/cam4.70031.

References

El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S, Munoz-Pinedo C . Sugar-free approaches to cancer cell killing. Oncogene. 2010; 30(3):253-64. DOI: 10.1038/onc.2010.466. View

Hamada K, Tomita Y, Qiu Y, Zhang B, Ueda T, Myoui A . 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II. Ann Nucl Med. 2008; 22(8):699-705. DOI: 10.1007/s12149-008-0173-9. View

Pastorino J, Hoek J . Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr. 2008; 40(3):171-82. PMC: 2662512. DOI: 10.1007/s10863-008-9148-8. View

Neary C, Pastorino J . Nucleocytoplasmic shuttling of hexokinase II in a cancer cell. Biochem Biophys Res Commun. 2010; 394(4):1075-81. PMC: 2873843. DOI: 10.1016/j.bbrc.2010.03.129. View

Suh D, Kim H, Chung H, Kim J, Park N, Song Y . Body mass index and survival in patients with epithelial ovarian cancer. J Obstet Gynaecol Res. 2011; 38(1):70-6. DOI: 10.1111/j.1447-0756.2011.01628.x. View

Pedersen P . Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr. 2007; 39(3):211-22. DOI: 10.1007/s10863-007-9094-x. View

Paudyal B, Oriuchi N, Paudyal P, Higuchi T, Nakajima T, Endo K . Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography. Cancer Sci. 2008; 99(2):260-6. PMC: 11159204. DOI: 10.1111/j.1349-7006.2007.00683.x. View

Smith T . Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 2000; 57(2):170-8. View

Kim J, Gao P, Dang C . Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev. 2007; 26(2):291-8. DOI: 10.1007/s10555-007-9060-4. View

10.

Jawhar N . Tissue Microarray: A rapidly evolving diagnostic and research tool. Ann Saudi Med. 2009; 29(2):123-7. PMC: 2813639. DOI: 10.4103/0256-4947.51806. View

11.

Mathupala S, Ko Y, Pedersen P . Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol. 2008; 19(1):17-24. PMC: 2714668. DOI: 10.1016/j.semcancer.2008.11.006. View

12.

Gong L, Cui Z, Chen P, Han H, Peng J, Leng X . Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II. Med Oncol. 2011; 29(2):909-14. DOI: 10.1007/s12032-011-9841-z. View

13.

Rho M, Kim J, Jee C, Lee Y, Lee H, Kim M . Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. Anticancer Res. 2007; 27(1A):251-8. View

14.

Shulga N, Wilson-Smith R, Pastorino J . Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism. Cell Cycle. 2009; 8(20):3355-64. PMC: 2829766. DOI: 10.4161/cc.8.20.9853. View

15.

Milane L, Duan Z, Amiji M . Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One. 2011; 6(9):e24075. PMC: 3169576. DOI: 10.1371/journal.pone.0024075. View

16.

Karantanis D, Allen-Auerbach M, Czernin J . Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma. Clin Nucl Med. 2011; 37(1):49-53. DOI: 10.1097/RLU.0b013e3182291e03. View

17.

Ahn K, Hwang H, Park J, Bang S, Kang W, Yun M . Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines. J Nucl Med. 2009; 50(9):1525-32. DOI: 10.2967/jnumed.108.060780. View

18.

Pathania D, Millard M, Neamati N . Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev. 2009; 61(14):1250-75. DOI: 10.1016/j.addr.2009.05.010. View

19.

Peng S, Lai P, Pan H, Hsiao L, Hsu H . Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep. 2008; 19(4):1045-53. View

20.

Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R . Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011; 208(2):313-26. PMC: 3039857. DOI: 10.1084/jem.20101470. View